Sarcocystosis (ICD-11: 1A34) - Complete Coding and Diagnostic Guide

1. Introduction

Sarcocystosis is a parasitic infection caused by protozoans of the genus Sarcocystis, a group of coccidia that presents a complex life cycle involving two hosts: a definitive and an intermediate host. This condition represents a significant diagnostic challenge in clinical practice, as its manifestations vary drastically depending on the role of the human in the parasitic cycle.

Although relatively underdiagnosed, sarcocystosis has considerable clinical importance, especially in regions where there is greater contact between humans and animals. Human infection can occur in two distinct forms: as a definitive host, when the individual ingests meat contaminated with tissue cysts, resulting in intestinal infection that is usually asymptomatic; or as an intermediate host, when there is ingestion of sporulated oocysts present in water or food contaminated with feces from carnivores, leading to the formation of muscle cysts and more severe clinical manifestations.

The exact prevalence of sarcocystosis remains uncertain due to the lack of systematic surveillance and diagnostic difficulty. Serological studies suggest that exposure to the parasite is more common than clinically recognized, with many cases remaining undiagnosed. Muscle infection (extraintestinal sarcocystosis) can cause myalgia, weakness, fever, and eosinophilia, while the intestinal form tends to be self-limited.

Correct coding of sarcocystosis is critical for multiple aspects of medical care: it enables appropriate epidemiological tracking, facilitates research on prevalence and geographic distribution, aids in public health resource planning, ensures appropriate reimbursement for services provided, and contributes to the global understanding of this neglected parasitosis. The ICD-11 code 1A34 was specifically designated for this condition, providing greater precision in clinical documentation.

2. Correct ICD-11 Code

Code: 1A34

Description: Sarcocystosis

Parent category: Intestinal infections by protozoa

Official definition: Refers to an infection by the protozoan genus Sarcocystis. The parasite reproduces sexually in the intestine of the definitive host, is eliminated through feces and ingested by the intermediate host. The definitive host usually does not present symptoms of infection, but the intermediate host does.

Code 1A34 is part of the chapter on infectious and parasitic diseases of ICD-11, specifically within the section of intestinal infections by protozoa. This classification reflects the primary nature of the infection, even when extraintestinal manifestations occur. The hierarchical structure facilitates the location of the code and its differentiation from other intestinal parasitoses.

It is important to understand that this code encompasses both intestinal sarcocystosis (when humans act as definitive hosts) and muscular or extraintestinal sarcocystosis (when humans act as accidental intermediate hosts). Both forms are coded under 1A34, as they represent different manifestations of the same parasitic infection. Clinical documentation should specify which form is present, although the code remains the same.

3. When to Use This Code

Code 1A34 should be applied in specific clinical situations where there is confirmation or strong clinical suspicion of Sarcocystis infection. Below are detailed practical scenarios:

Scenario 1: Intestinal sarcocystosis confirmed by parasitological examination A patient presents with mild diarrhea, nausea, and abdominal discomfort after consuming undercooked meat. Parasitological stool examination identifies sporozoites or oocysts of Sarcocystis. This is the most straightforward scenario for applying code 1A34, as there is definitive laboratory confirmation of intestinal infection.

Scenario 2: Muscular sarcocystosis with positive biopsy Patient with a history of persistent myalgia, progressive muscle weakness, and low-grade fever. Investigation includes muscle biopsy revealing Sarcocystis cysts in muscle tissues. Complementary tests show peripheral eosinophilia. In this case, code 1A34 is appropriate, as it documents the extraintestinal form of infection, where the human acts as an accidental intermediate host.

Scenario 3: Presumptive diagnosis based on epidemiological and clinical criteria An individual develops acute gastrointestinal symptoms (nausea, vomiting, diarrhea, abdominal cramps) 6 to 48 hours after consuming raw or undercooked meat in an endemic area. Although parasitological examination may be negative due to the short period of sporozoite shedding, the clinical-epidemiological context justifies presumptive diagnosis and coding as 1A34.

Scenario 4: Asymptomatic infection detected incidentally During investigation of unexplained eosinophilia or in routine examinations, shedding of Sarcocystis sporozoites is identified in stool, even without gastrointestinal symptoms. Code 1A34 remains applicable, as it documents confirmed parasitic infection, regardless of the absence of clinical manifestations.

Scenario 5: Epidemic outbreak with multiple related cases Various individuals who shared a meal containing contaminated meat develop similar gastrointestinal symptoms. Epidemiological investigation identifies Sarcocystis as the etiological agent in at least some laboratory-confirmed cases. All epidemiologically linked cases may be coded as 1A34, even those without individual laboratory confirmation.

Scenario 6: Systemic manifestations with positive serology Patient presents with prolonged fever, diffuse myalgias, intense fatigue, and marked eosinophilia. Serological tests demonstrate specific antibodies against Sarcocystis at elevated titers, especially when documented seroconversion is present. Even without direct parasite isolation, the combination of clinical manifestations and serological evidence justifies code 1A34.

4. When NOT to Use This Code

It is essential to distinguish sarcocystosis from other conditions that may present with similar clinical manifestations but require different coding:

Other intestinal protozoal infections: Code 1A34 should not be used for infections caused by other intestinal protozoa. Giardiasis (1A31), cryptosporidiosis (1A32), infections by Balantidium coli (1A30), amebiasis (1A36), and other intestinal parasitoses have specific codes and should not be classified as sarcocystosis.

Toxoplasmosis: Although Toxoplasma gondii is also a related coccidian, toxoplasmosis has completely different coding and should not be confused with sarcocystosis. The clinical manifestations, life cycle, and clinical implications are distinct, especially in immunocompromised patients and pregnant women.

Trichinosis: Infection by Trichinella can cause myalgia, fever, and eosinophilia, mimicking muscular sarcocystosis. However, it is a helminthic infection, not protozoal, and requires a specific code. Differentiation is made by muscle biopsy or specific serology.

Idiopathic inflammatory myopathies: Polymyositis, dermatomyositis, and other autoimmune myopathies may present with muscle weakness and elevated muscle enzymes. These conditions are not infectious and require codes from the category of muscular diseases, not parasitic.

Viral or bacterial gastroenteritis: Acute gastrointestinal symptoms may be caused by various pathogens. Without specific evidence of Sarcocystis, appropriate codes should be used for infectious gastroenteritis of another etiology or of unspecified etiology.

Eosinophilia from other causes: Eosinophilia may result from multiple conditions, including other parasitoses, allergic reactions, hematological diseases, and medications. Code 1A34 should only be applied when there is evidence of infection by Sarcocystis.

5. Step-by-Step Coding Process

Step 1: Assess diagnostic criteria

The diagnosis of sarcocystosis requires confirmation or strong suspicion based on specific criteria. For the intestinal form, the gold standard is microscopic identification of Sarcocystis sporozoites or oocysts in parasitological stool examinations. These are generally eliminated for a limited period (up to 2 weeks after infection), making the timing of collection crucial.

For muscular sarcocystosis, muscle tissue biopsy revealing characteristic cysts provides definitive diagnosis. The cysts present typical morphology with internal compartmentalization visible on microscopy. Serological tests can detect specific antibodies, although standardization and availability are limited. Peripheral eosinophilia, although nonspecific, is a common finding and supports the diagnosis when present.

Clinical criteria include compatible epidemiological history (consumption of raw or undercooked meat), characteristic manifestations (acute gastroenteritis for intestinal form; myalgia, weakness, and fever for muscular form), and exclusion of other more common etiologies.

Step 2: Verify specifiers

Documentation must specify which form of sarcocystosis is present: intestinal (definitive host) or muscular/extraintestinal (intermediate host). This distinction is clinically relevant, as the prognostic and therapeutic implications differ significantly.

Severity must be documented: asymptomatic infection, mild self-limited symptoms, moderate disease requiring symptomatic treatment, or severe disease with significant systemic involvement. Duration of symptoms and response to treatment should also be recorded.

Complications, when present, must be documented separately with additional codes. These may include dehydration secondary to diarrhea, severe muscular involvement with functional impairment, or systemic manifestations such as myocarditis (rare, but described).

Step 3: Differentiate from other codes

1A30 - Balantidium coli infections: This infection is caused by a ciliated protozoan, not a coccidian. Clinically, it can cause more severe diarrhea, often bloody, with colonic ulcerations. Differential diagnosis is made by microscopic identification of the characteristic trophozoite or cyst of B. coli in stool, which has completely distinct morphology from Sarcocystis sporozoites.

1A31 - Giardiasis: Caused by Giardia lamblia, characterized by chronic diarrhea, steatorrhea, abdominal distension, and malabsorption. The course is typically more prolonged than intestinal sarcocystosis. Diagnosis is confirmed by identification of Giardia cysts or trophozoites in stool or by specific antigen tests, which are morphologically distinct.

1A32 - Cryptosporidiosis: Infection by Cryptosporidium causes profuse watery diarrhea, especially in immunocompromised individuals. Cryptosporidium oocysts are much smaller (4-6 μm) than Sarcocystis sporozoites and require special stains (modified Ziehl-Neelsen) for visualization. Sarcocystosis generally does not cause such voluminous diarrhea.

Step 4: Required documentation

Checklist of mandatory information:

Date of symptom onset
Detailed description of clinical manifestations
Epidemiological history (meat consumption, animal exposure)
Results of parasitological stool examinations (method used, number of samples)
Results of muscle biopsy, if performed
Results of serological tests, if available
Relevant laboratory findings (eosinophilia, muscle enzymes)
Sarcocystis species identified, if possible
Form of infection (intestinal vs. muscular)
Severity and complications
Treatment instituted and therapeutic response

Adequate documentation not only justifies coding but also facilitates epidemiological studies and improves understanding of this still poorly characterized parasitosis.

6. Complete Practical Example

Clinical Case

A 42-year-old male patient, a farmer, presents to the health service with complaints of generalized muscle pain, progressive weakness, and intermittent low-grade fever for 3 weeks. He reports that symptoms began gradually, with a sensation of intense fatigue, progressing to diffuse muscle pain, more intense in the lower limbs and shoulder girdle. He denies diarrhea but mentions an episode of nausea and mild abdominal discomfort approximately 6 weeks ago, which resolved spontaneously.

On directed history, he reports regular consumption of pork and beef, frequently undercooked, from his own farm. He denies recent travel or contact with sick individuals. On physical examination, he appears in fair general condition, febrile (38.2°C), with diffuse muscle tenderness on palpation, without signs of arthritis. Muscle strength is preserved, but he reports difficulty performing usual activities due to pain.

Initial laboratory tests reveal leukocytosis (12,500/mm³) with marked eosinophilia (18% - 2,220/mm³), elevated creatine phosphokinase (CPK: 850 U/L) and aldolase (32 U/L). Renal and hepatic function tests are normal. Parasitological stool examination was negative (collection late relative to the possible period of infection).

Due to persistence of symptoms and unexplained eosinophilia, a muscle biopsy of the quadriceps was performed, which revealed the presence of sarcocystic cysts in muscle tissue, with morphology compatible with Sarcocystis spp. The diagnosis of muscular sarcocystosis was established.

Step-by-Step Coding

Analysis of criteria:

Diagnostic confirmation by muscle biopsy: present
Compatible clinical manifestations: myalgia, weakness, fever
Significant eosinophilia: present
Elevation of muscle enzymes: present
Compatible epidemiological history: consumption of undercooked meat
Exclusion of other causes: performed

Code selected: 1A34 - Sarcocystosis

Complete justification: Code 1A34 is appropriate because the patient presents with histopathological confirmation of Sarcocystis infection, characterizing muscular sarcocystosis (extraintestinal form). The clinical presentation is typical of this manifestation, with myalgia, weakness, fever, and eosinophilia. The history of consuming undercooked meat is compatible with the transmission mechanism. The negative parasitological stool examination does not exclude the diagnosis, as the collection was late and the patient acts as an intermediate host (does not shed sporocysts in feces). The muscle biopsy provides definitive confirmation.

Complementary codes:

Code for eosinophilia, if relevant for additional documentation
Code for myalgia, if necessary to document main symptom
Codes for procedures performed (muscle biopsy)

7. Related Codes and Differentiation

Within the Same Category

1A30: Balantidium coli Infections

When to use: Use 1A30 when there is microscopic identification of Balantidium coli (large ciliated trophozoites or cysts) in stool. Clinically, balantidiasis tends to cause more severe colitis, with bloody diarrhea and intestinal ulcerations visible on colonoscopy.

Main difference: B. coli is a ciliated protozoan with completely distinct morphology, whereas Sarcocystis is a coccidian. Balantidiasis does not cause muscular manifestations, unlike sarcocystosis. Transmission of B. coli is associated with contact with pigs, whereas Sarcocystis is related to consumption of contaminated meat.

1A31: Giardiasis

When to use: Code 1A31 should be applied when there is confirmed infection with Giardia lamblia, whether by microscopic identification of cysts/trophozoites in stool, detection of specific antigens, or molecular testing. Clinically, it is characterized by chronic diarrhea, flatulence, abdominal distension, and malabsorption.

Main difference: Giardiasis is typically a chronic duodenal infection with symptoms persisting for weeks to months, whereas intestinal sarcocystosis is generally self-limited within a few days. Giardia does not cause eosinophilia or muscular manifestations. The organisms are morphologically distinct on microscopic examination.

1A32: Cryptosporidiosis

When to use: Use 1A32 when Cryptosporidium is identified in stool by special stains (modified Ziehl-Neelsen), immunofluorescence, or PCR. It is particularly relevant in immunocompromised patients with profuse and prolonged watery diarrhea.

Main difference: Cryptosporidium causes much more voluminous and prolonged diarrhea, especially in immunosuppressed individuals, and can be fatal. Oocysts are much smaller (4-6 μm) than Sarcocystis sporocysts and require special stains. It does not cause eosinophilia or muscular manifestations.

Differential Diagnoses

Toxoplasmosis: Although also caused by a coccidian, it presents with completely different manifestations (lymphadenopathy, chorioretinitis, encephalitis in immunosuppressed patients). Transmission, life cycle, and codes are distinct.

Trichinosis: Can mimic muscular sarcocystosis with myalgia, fever, and eosinophilia, but is caused by a helminth (Trichinella). It is differentiated by history of consumption of pork or game meat, characteristic periorbital edema, and specific findings on biopsy or serology.

Cysticercosis: Caused by larvae of Taenia solium, can affect muscles but typically involves the central nervous system. Radiological imaging shows characteristic calcifications, and cyst morphology is distinct.

8. Differences with ICD-10

In ICD-10, sarcocystosis was coded as A07.8 (Other specified intestinal diseases due to protozoa) or possibly as B60.8 (Other specified diseases due to protozoa), depending on the clinical presentation and the coder's interpretation. This lack of specificity hindered epidemiological tracking and research on the condition.

The main change in ICD-11 is the creation of the specific code 1A34 exclusively for sarcocystosis, providing greater diagnostic precision and facilitating epidemiological studies. This specificity recognizes the clinical importance of the condition and allows better differentiation from other intestinal parasitoses.

Another significant change is the clearer hierarchical structure in ICD-11, where sarcocystosis is explicitly categorized under "Intestinal infections due to protozoa," even when presenting with extraintestinal manifestations. This reflects the understanding that the primary infection is intestinal, with possible systemic dissemination.

The practical impact of these changes includes better case traceability, facilitation of research on prevalence and geographic distribution, greater precision in public health reports, and reduction of ambiguity in coding. For health professionals, it means more accurate documentation and potentially better recognition of the condition by health systems and insurance companies.

9. Frequently Asked Questions

How is sarcocystosis diagnosed?

The diagnosis varies according to the form of infection. In intestinal sarcocystosis, the gold standard is microscopic identification of sporozoites or oocysts in stool, although these are shed only for a limited period (usually up to 2 weeks after infection). Multiple samples may be necessary. In muscular sarcocystosis, biopsy of symptomatic muscle tissue revealing characteristic cysts provides definitive diagnosis. Serological tests can detect specific antibodies, but their availability is limited and interpretation requires experience. Clinical findings (myalgia, fever, eosinophilia) and epidemiological history (consumption of undercooked meat) support the diagnosis, but are not specific.

Is treatment available in public health systems?

Intestinal sarcocystosis is generally self-limited and requires only symptomatic treatment (hydration, antiemetics, analgesics), which is widely available in public health systems. For the muscular form, there is no proven effective specific antiparasitic treatment. Management is primarily symptomatic with analgesics, anti-inflammatory agents, and occasionally corticosteroids for severe cases. Some studies suggest potential benefit of cotrimoxazole or albendazole, but evidence is limited. These medications, when used, are generally available in public health systems.

How long does treatment last?

For intestinal sarcocystosis, symptomatic treatment is maintained until symptom resolution, typically 3 to 7 days. The infection is self-limited and does not require specific antiparasitics in most cases. In muscular sarcocystosis, symptomatic treatment may be necessary for several weeks to months, depending on severity and clinical response. If antiparasitics are used empirically, courses vary: cotrimoxazole may be used for 2 to 4 weeks, while albendazole may be administered for 1 to 2 weeks. Treatment response is monitored clinically through symptom improvement, reduction of eosinophilia, and normalization of muscle enzymes.

Can this code be used in medical certificates?

Yes, code 1A34 can and should be used in medical certificates when there is confirmed or strongly suspected diagnosis of sarcocystosis. Appropriate documentation justifies work absence, especially in cases of muscular sarcocystosis with significant functional impairment. It is important that the certificate specify the nature of the condition in an understandable manner, although the ICD-11 code provides precise technical classification. For patients with occupations involving food handling, there may be a need for temporary absence during the acute phase of intestinal disease.

Is sarcocystosis contagious between humans?

No, sarcocystosis is not transmitted directly from person to person. Transmission requires the complete parasite cycle involving definitive hosts (carnivores) and intermediate hosts (herbivores or omnivores). Humans acquire intestinal infection by consuming raw or undercooked meat containing tissue cysts, or develop the muscular form by ingesting oocysts present in water or food contaminated with feces from infected carnivores. Therefore, there is no need for contact isolation, and family members are not at risk from living with an infected person.

Is there a risk of reinfection?

Yes, there is no lasting immunity against sarcocystosis, and reinfections are possible with new exposure to the parasite. Individuals who maintain risky eating habits (consumption of raw or undercooked meat) or live in areas with inadequate sanitation remain susceptible to new infections. Prevention depends on permanent measures: adequate cooking of meat (internal temperature above 70°C), prolonged freezing (below -20°C for several days), proper food and water hygiene, and appropriate environmental sanitation.

How to differentiate sarcocystosis from other causes of myalgia and eosinophilia?

Differentiation requires a systematic approach. Epidemiological history of undercooked meat consumption favors sarcocystosis or trichinosis. Travel to tropical areas suggests other parasitic diseases. Specific tests are essential: stool parasitology for helminths, serology for Trichinella and Toxoplasma, muscle biopsy for direct visualization of parasites. Muscular sarcocystosis typically presents with less intense eosinophilia than trichinosis, absence of periorbital edema (characteristic of trichinosis), and generally more protracted course. Autoimmune myopathies are differentiated by specific patterns on muscle biopsy, absence of relevant epidemiological history, and frequently the presence of autoantibodies.

Can sarcocystosis cause serious complications?

Intestinal sarcocystosis rarely causes significant complications, being generally self-limited. The muscular form can occasionally result in important functional impairment due to intense myalgia and weakness, affecting quality of life and work capacity. Rare but described complications include myocarditis (inflammation of cardiac muscle), central nervous system involvement, and vasculitis. Immunocompromised patients may present with more severe and prolonged disease. Most cases, however, evolve to complete resolution with appropriate symptomatic treatment, although recovery time may vary from weeks to months in the muscular form.

Conclusion

Sarcocystosis represents a parasitic disease of increasing clinical importance, especially as diagnostic methods become more accessible and awareness increases. Precise coding using ICD-11 code 1A34 is fundamental for appropriate documentation, epidemiological tracking, and appropriate allocation of health resources. Understanding the differences between intestinal and muscular forms, specific diagnostic criteria, and differentiation from other intestinal parasitic diseases enables health professionals to provide appropriate care and contribute to global knowledge about this still underdiagnosed condition. Prevention through appropriate food preparation practices and environmental sanitation remains the most effective strategy to reduce the incidence of this parasitic infection.

External References

This article was prepared based on reliable scientific sources:

References verified on 2026-02-04

Sarcocystosis

Partager